oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins
Medical Biotechnology, VTT Technical Research Centre of Finland, Turku Centre for Biotechnology, University of Turku, Finland.
Medical Biotechnology, VTT Technical Research Centre of Finland, Turku Centre for Biotechnology, University of Turku, Finland.
Haartman Institute, Department of Pathology, University of Helsinki, Finland; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland; HUSLAB, Department of Pathology, Helsinki University Central Hospital, Finland.
Bio and Process Technology, VTT Technical Research Centre of Finland, Espoo, Finland.
Show others and affiliations
2011 (English)In: OncoTarget, ISSN 1949-2553, E-ISSN 1949-2553, Vol. 2, no 12, 1176-1190 p.Article in journal (Refereed) Published
Abstract [en]

Prostate cancer is the second leading cause of cancer mortality in men in developed countries. Due to the heterogeneous nature of the disease, design of novel personalized treatments is required to achieve efficient therapeutic responses. We have recently identified phospholipase 2 group VII (PLA2G7) as a potential drug target especially in ERG oncogene positive prostate cancers. Here, the expression profile of PLA2G7 was studied in 1137 prostate cancer and 409 adjacent non-malignant prostate tissues using immunohistochemistry to validate its biomarker potential and putative association with disease progression. In order to reveal the molecular alterations induced by PLA2G7 impairment, lipidomic and gene expression profiling was performed in response to PLA2G7 silencing in cultured prostate cancer cells. Moreover, the antineoplastic effect of statins combined with PLA2G7 impairment was studied in prostate cancer cells to evaluate the potential of repositioning of in vivo compatible drugs developed for other indications towards anti-cancer purposes. The results indicated that PLA2G7 is a cancer-selective biomarker in 50 % of prostate cancers and associates with aggressive disease. The alterations induced by PLA2G7 silencing highlighted the potential of PLA2G7 inhibition as an anti-proliferative, pro-apoptotic and anti-migratorial therapeutic approach in prostate cancer. Moreover, the anti-proliferative effect of PLA2G7 silencing was potentiated by lipid-lowering statins in prostate cancer cells. Taken together, our results support the potential of PLA2G7 as a biomarker and a drug target in prostate cancer and present a rationale for combining PLA2G7 inhibition with the use of statins in prostate cancer management.

Place, publisher, year, edition, pages
Impact Journals LLC , 2011. Vol. 2, no 12, 1176-1190 p.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-63657DOI: 10.18632/oncotarget.397PubMedID: 22202492Scopus ID: 2-s2.0-84861380745OAI: oai:DiVA.org:oru-63657DiVA: diva2:1169220
Available from: 2017-12-22 Created: 2017-12-22 Last updated: 2018-01-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Authority records BETA

Oresic, Matej

Search in DiVA

By author/editor
Oresic, Matej
In the same journal
OncoTarget
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 1 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf